Just one in three patients with gout in the UK received preventative medication within a year of diagnosis, new research has found.
The study is published today in The Lancet Regional Health – Europe journal by researchers from King’s and with funding from the National Institute for Health and Care Research (NIHR), the research partner of the NHS, public health and social care.
Gout is the most common form of inflammatory arthritis in the UK, affecting 1 in 40 people. People with gout experience recurrent flares of severe joint pain and swelling, which can lead to joint damage and functional impairment if undertreated or not treated at all. Gout is also associated with other conditions, including chronic kidney disease.
In people with gout, flares can be prevented with highly effective, low-cost, urate-lowering medications, such as allopurinol. However, previous studies highlighted that only a minority of people with gout were started on these medications, leaving them at risk of ongoing flares. In 2012, just 27% of people with gout in the UK received prescriptions for urate-lowering medications. Because of this, European and British gout management guidelines were updated in 2016 and 2017, to encourage the prescription of these medications.
Researchers from King’s used the Clinical Practice Research Datalink, a health database of people registered with over 2000 general practices in the UK, to determine whether care for people with gout had improved since the guidelines were published. They were able to evaluate the management of 129,000 people with newly diagnosed gout in the UK between 2004 and 2020.
The results showed only a modest improvement in the prescription of urate-lowering medications over the study period, from 27% of patients diagnosed in 2004, to 37% in 2019. This was followed by a reduction in prescriptions in 2020, with 35% of patients being prescribed medication, which may reflect reduced access to care because of the COVID-19 pandemic.
Researchers also showed that just one in six patients achieved the target blood urate level recommended by the British Society for Rheumatology. People with other medical conditions, such as heart failure and kidney disease, were more likely to be prescribed medication than those without co-morbidities, however they were less likely to achieve these target urate levels.
The findings suggest that the quality and success of gout care in the UK remain poor despite updated guidelines. This problem is not limited to people with gout who are managed in primary care; other studies have shown that patients managed in specialist clinics frequently do not achieve the target urate levels necessary to prevent flares and damage.
These results were quite surprising as the initiation of treatment is straightforward, and the medications we use to treat and prevent gout have been around for decades, and are cheap. Our data indicate that we have a lot more work to do. Strategies are needed to encourage the prescription of preventative medications in people with gout. For example, educational programmes could help to raise awareness about the importance of medications such as allopurinol in the prevention of recurrent flares and disability due to gout.– Dr Mark Russell, from the School of Immunology & Microbial Sciences
Senior author Dr James Galloway from School of Immunology & Microbial Sciences added: “This study highlights the value of large datasets from primary care, and how applying analytical tools can uncover major challenges with the treatment of what are, in essence, very common inflammatory diseases. Reassuringly, these challenges are not so difficult to fix, and could have a huge impact on tens of thousands of people suffering from this condition across the country.”